A Phase 1 interventional study of VIS954 and Placebo in Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a first-in-human (FIH), randomized, placebo-controlled, double-blind, single ascending dose (SAD) study to assess the safety and tolerability of VIS954, a monoclonal antibody, in healthy adult male and female participants.
The study will be conducted in 6 sequential cohorts. Each cohort will enroll 9 participants, randomized to VIS954 or placebo at a ratio of 7:2.
On Day 1, a single dose of VIS954 or placebo will be administered SC. Sentinel participants will be utilized in each cohort. After 14 days, the safety data will be evaluated and a decision to admit and dose the next cohort will be made.
The total duration of the clinical study per participant will be up to 102 days (approximately 4 months).
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Coronavirus disease 2019:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single VIS954 Dose 1 will be administered subcutaneously on Day 1
Biological: VIS954
A single VIS954 Dose 2 will be administered subcutaneously on Day 1
Biological: VIS954
A single VIS954 Dose 3 will be administered subcutaneously on Day 1
Biological: VIS954
A single VIS954 Dose 4 will be administered subcutaneously on Day 1
Biological: VIS954
A single VIS954 Dose 5 will be administered subcutaneously on Day 1
Biological: VIS954
A single VIS954 Dose 6 will be administered subcutaneously on Day 1
Biological: VIS954
A single Placebo dose will be administered subcutaneously on Day 1 for 2 participants in each cohort.
Other: Placebo
A humanized IgG4 monoclonal antibody.
VIS954 Placebo
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product or was an important medical event that jeopardized the participant or required medical or surgical intervention to prevent 1 of the other outcomes listed above. TEAEs were AEs that first occurred or worsened in severity after the study intervention administration, and up to Day 71 (including the follow-up period) after the study intervention administration.
Time frame: From study intervention administration (Day 1) up to end of follow-up (Day 71)
Wong-Baker FACES Pain Rating Scale
The Wong-Baker FACES Pain Rating Scale was a subjective self-report that was used to record each participant's perception of pain associated with their injection. The scale ranged from 0 to 10 and showed a series of faces ranging from a happy face at 0 which represented "no hurt" to a crying face at 10 which represented "hurts worst." Based on the faces and descriptions, the participant recorded their level of pain. Higher scores indicated more severe pain.
Time frame: Day 1 (1 and 4 hours post-dose), Day 2 (24 hours post-dose), and on Days 3 and 29
Maximum Serum Concentration (Cmax) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The pharmacokinetic (PK) parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Time of Maximum Serum Concentration (Tmax) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Area Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Area Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Apparent Terminal Elimination Half-Life (t1/2) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Apparent Volume of Distribution (Vd/F) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Apparent Clearance After Extravascular Dosing (CL/F) of VIS954
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Time Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils
Blood samples were collected at the specified time points to characterize the effect of VIS954 binding. The time spent above 40% RO was defined as duration in hours from date and time of dosing until the date and time of pharmacodynamic (PD) collection when %RO \>40%. Baseline was defined as the last non-missing measurement taken prior to reference start date (including unscheduled assessments).
Time frame: Baseline (Day -1) up to Day 71
This Phase 1, double-blind, single ascending dose, first-in-human study was conducted in healthy participants at a single investigational site.
| Milestone | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 | 12 |
| Completed | 7 | 7 | 7 | 7 | 7 | 7 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product or was an important medical event that jeopardized the participant or required medical or surgical intervention to prevent 1 of the other outcomes listed above. TEAEs were AEs that first occurred or worsened in severity after the study intervention administration, and up to Day 71 (including the follow-up period) after the study intervention administration.
| Participants | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| TEAEs | 2 | 1 | 1 | 1 | 3 | 2 | 4 |
| TESAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The Wong-Baker FACES Pain Rating Scale was a subjective self-report that was used to record each participant's perception of pain associated with their injection. The scale ranged from 0 to 10 and showed a series of faces ranging from a happy face at 0 which represented "no hurt" to a crying face at 10 which represented "hurts worst." Based on the faces and descriptions, the participant recorded their level of pain. Higher scores indicated more severe pain.
| units on a scale | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Day 1: 1 hour post-dose | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0.3 ± 0.8 | 0 ± 0 | 0 ± 0 | 0.3 ± 1.2 |
| Day 1: 4 hours post-dose | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0.3 ± 1.2 |
| Day 2: 24 hours post-dose | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Day 3 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Day 29 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The pharmacokinetic (PK) parameters of VIS954 were derived using noncompartmental analysis method.
| micrograms per milliliter (mcg/mL) | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Maximum Serum Concentration (Cmax) of VIS954 | — | 0.0660 ± NA | 1.961 ± 1.378 | 4.423 ± 2.851 | 16.82 ± 12.95 | 32.61 ± 12.00 |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
| hour | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Time of Maximum Serum Concentration (Tmax) of VIS954 | — | 48.00 (48.00 to 48.00) | 48.00 (4.02 to 98.35) | 71.82 (48.00 to 166.38) | 74.02 (72.12 to 169.70) | 95.60 (48.00 to 169.70) |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
| hour*mcg/mL | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954 | — | — | 395 ± NA | 1463 ± 1324 | 5529 ± 1877 | 11560 ± 5503 |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
| hour*mcg/mL | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954 | — | 3.17 ± NA | 188.4 ± 151.2 | 872.4 ± 974.1 | 3604 ± 2684 | 11470 ± 5458 |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
| hour | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Apparent Terminal Elimination Half-Life (t1/2) of VIS954 | — | — | 85.25 (37.5 to 133) | 33.6 (25.8 to 105) | 48.0 (41.3 to 82.4) | 76.3 (44.7 to 101) |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
| liter | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) of VIS954 | — | — | 12.3 ± NA | 10.12 ± 1.797 | 5.218 ± 1.606 | 8.536 ± 5.579 |
Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
| liter per hour | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 |
|---|---|---|---|---|---|---|
| Apparent Clearance After Extravascular Dosing (CL/F) of VIS954 | — | — | 0.228 ± NA | 0.1864 ± 0.1108 | 0.06911 ± 0.02358 | 0.07976 ± 0.05542 |
Blood samples were collected at the specified time points to characterize the effect of VIS954 binding. The time spent above 40% RO was defined as duration in hours from date and time of dosing until the date and time of pharmacodynamic (PD) collection when %RO \>40%. Baseline was defined as the last non-missing measurement taken prior to reference start date (including unscheduled assessments).
| hour | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Time Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils | 0.0 (0.0 to 0.0) | 48.0 (0.0 to 74.1) | 239.2 (215.8 to 314.1) | 335.5 (239.7 to 671.4) | 503.1 (217.0 to 673.7) | 1008.1 (838.9 to 1680.0) | 0.0 (0.0 to 0.0) |
Collected over From study intervention administration (Day 1) up to end of follow-up (Day 71). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: VIS954 Dose 1 | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Cohort 2: VIS954 Dose 2 | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Cohort 3: VIS954 Dose 3 | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Cohort 4: VIS954 Dose 4 | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Cohort 5: VIS954 Dose 5 | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Cohort 6: VIS954 Dose 6 | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Cohort 1 to 6: Pooled Placebo | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 0/7 | 0/7 | 0/7 | 1/7 | 2/7 | 1/7 | 3/12 |
| Blood loss anaemiaBlood and lymphatic system disorders | 0/7 | 1/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 0/7 | 0/7 | 1/7 | 0/7 | 0/7 | 0/12 |
| Injection site bruisingGeneral disorders | 1/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/12 |
| Injection site pruritusGeneral disorders | 0/7 | 0/7 | 0/7 | 1/7 | 0/7 | 0/7 | 1/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/7 | 0/7 | 0/7 | 0/7 | 1/7 | 0/7 | 0/12 |
| HeadacheNervous system disorders | 1/7 | 0/7 | 1/7 | 0/7 | 0/7 | 0/7 | 1/12 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 1/7 | 0/12 |
| NauseaGastrointestinal disorders | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 1/12 |
| Upper respiratory tract infectionInfections and infestations | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 1/12 |
The safety analysis set included all participants who received trial intervention (active or placebo).
| Age, Continuous(years) | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 35.4 ± 8.2 | 40.6 ± 8.1 | 38.9 ± 9.6 | 39.0 ± 7.7 | 39.4 ± 9.3 | 39.0 ± 10.2 | 36.5 ± 7.6 | 38.2 ± 8.3 |
| Sex: Female, Male(Participants) | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 5 | 4 | 4 | 4 | 2 | 3 | 7 | 29 |
| Male | 2 | 3 | 3 | 3 | 5 | 4 | 5 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 | 1 | 2 | 3 | 10 |
| Not Hispanic or Latino | 6 | 6 | 7 | 5 | 6 | 5 | 9 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: VIS954 Dose 1 | Cohort 2: VIS954 Dose 2 | Cohort 3: VIS954 Dose 3 | Cohort 4: VIS954 Dose 4 | Cohort 5: VIS954 Dose 5 | Cohort 6: VIS954 Dose 6 | Cohort 1 to 6: Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Black | 1 | 3 | 2 | 1 | 0 | 0 | 4 | 11 |
| Asian | 4 | 3 | 2 | 4 | 6 | 3 | 1 | 23 |
| White | 2 | 1 | 1 | 1 | 1 | 3 | 5 | 14 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Multiple | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2023 to primary completion in Jul 2024, 7 months.
Results were first posted in Jul 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VIS954
Otsuka Pharmaceutical Development & Commercialization, Inc. →